Pegylated phosphoric acid prodrug as well as preparation and application thereof

By developing pegylated phosphate prodrugs, the problems of instability and insufficient bioavailability of Remdesivir in plasma were solved, effective inhibition and treatment effects of viral infection were achieved, and the synthesis route was simple and low cost.

CN118994243APending Publication Date: 2024-11-22HANGZHOU JUWEIYE BIOMEDICAL CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411047054.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-08-04
Filing Date
2024-08-01
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

The instability of Remdesivir in plasma causes it to require intravenous injection, and its oral bioavailability, insufficient pulmonary delivery and high hepatotoxicity are difficult to effectively improve through the prior art.

Method used

A pegylated phosphate prodrug has been developed to prepare a new compound for improving drug stability and bioavailability through specific steps and reaction conditions in the synthesis route and by subcutaneous, intravenous or oral administration. The dosing form provides a method to treat or prevent viral infection.

Benefits of technology

This compound has shown effective ability to inhibit feline infectious peritonitis virus infection in in vitro and in vivo experiments, and its synthetic route raw materials are easy to obtain, the reaction conditions are mild, and the cost is low, making it suitable for subsequent research and production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004973768290000011
    Figure BDA0004973768290000011
  • Figure BDA0004973768290000031
    Figure BDA0004973768290000031
  • Figure BDA0004973768290000041
    Figure BDA0004973768290000041
Patent Text Reader

Abstract

The present invention discloses a compound of formula I or a pharmaceutically acceptable salt; wherein R1 and R2 are mutually independently selected from H, or C1-C6 alkyl, 3-8-membered cycloalkyl or 6-20-membered aryl, and alkyl, cycloalkyl and aryl can be further substituted by one or more mutually independent substituent groups; m is an integer greater than 1; n is an integer greater than or equal to 0. The invention also discloses a preparation method and application of the compound or the pharmaceutically acceptable salt. The new pegylated phosphoric acid prodrug compound molecule is innovatively synthesized, and the synthesis route has the advantages of easily available raw materials, mild reaction conditions, simple operation and low cost, and is suitable for subsequent research and production. The innovative compounds and compositions thereof of the present invention are useful for the treatment or prevention of viral infections in humans or animals. The compound and the composition thereof can be used for effectively inhibiting feline infectious peritonitis virus (FIPV) infection and treating feline infectious peritonitis.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of antiviral drug research and development, and specifically relates to a pegylated phosphate prodrug and a preparation and application thereof. Background Art

[0002] Remdesivir is an FDA-approved antiviral drug used to treat severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) infection. The drug is an arylphosphoramidite triester prodrug that utilizes ProTide nucleotide prodrug technology to deliver the remdesivir nucleoside (RVn) candidate molecule. After administration, remdesivir releases RVn monophosphate, a precursor to the active RVn triphosphate that effectively inhibits the enzymatic activity of the polymerase of every coronavirus tested to date, including SARS CoV-2. However, due to the instability of remdesivir in plasma, it must be administered intravenously. Researchers are currently studying various prodrug approaches to improve its oral bioavailability, plasma instability, insufficient pulmonary delivery, and liver toxicity. Summary of the invention

[0003] Provided herein are PEGylated phosphate prodrugs of remdesivir nucleoside monophosphate that can be used in pharmaceutical compositions for treating or preventing viral infections in humans or animals.

[0004] In one aspect, the present invention provides a compound of formula I:

[0005]

[0006] or a pharmaceutically acceptable salt, wherein:

[0007] Each R1 and R2 is independently selected from H, or C1-C6 alkyl, 3-8 membered cycloalkyl or 6-20 membered aryl, or optional substituents thereof; the alkyl, cycloalkyl, aryl may be further substituted by one or more independent substituents;

[0008] m is an integer greater than 1; n is an integer greater than or equal to 0.

[0009] As an embodiment, m is 1, 2, 3, 4, 5, 6, 7, 8.

[0010] As an embodiment, n is 0, 1, 2, 3, 4, 5, 6, 7, 8.

[0011] The substituent group may be a variety of groups, such as alkyl (preferably C1-C6 alkyl), alkoxy (preferably C1-C6 alkoxy), carboxyl, ester (preferably containing 1-6 carbon atoms), hydroxyl, aldehyde, etc. For example, the optional substituent of phenyl may be phenyl, phenyl substituted with a single alkyl group, phenyl substituted with multiple alkyl groups, phenyl substituted with oxygen-containing groups (such as methoxy, carboxyl, ester, hydroxyl, aldehyde, etc.), phenyl substituted with multiple groups, etc. On the other hand, the present application provides a pharmaceutical preparation, comprising a pharmaceutically effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or excipient.

[0012] In another aspect, the present application provides the use of a compound of formula I or a pharmaceutically acceptable salt thereof for treating or preventing viral infections in humans or animals.

[0013] In another aspect, the present application provides a method for treating or preventing a viral infection in a human, wherein the method comprises administering a compound of Formula I or a pharmaceutically acceptable salt thereof to the human.

[0014] In another aspect, the present application provides a method for preparing and producing a pharmaceutical composition characterized by using a compound of Formula I or a pharmaceutically acceptable salt thereof.

[0015] The foregoing summary is illustrative only and is not intended to be limiting in any way. In addition to the illustrative aspects, embodiments, and features described above, further aspects, embodiments, and features will be revealed by reference to the drawings and the following detailed description.

[0016] The present disclosure relates to PEGylated phosphate prodrugs, and pharmaceutical compositions thereof can be used to treat or prevent viral infections in humans or animals.

[0017] definition

[0018] Unless otherwise indicated, the following terms and phrases used in this Agreement are intended to have the following meanings:

[0019] As used herein, "compounds of the present disclosure" or "compounds of Formula I" refers to compounds of Formula I or pharmaceutically acceptable salts thereof. Similarly, the phrase "compounds of Formula (number)" refers to compounds shown in the formula and pharmaceutically acceptable salts thereof.

[0020] As used herein, "salt" refers to a solid containing equal amounts of anions and cations. A salt can be a "single component" solid. A salt can also be a "multi-component" solid containing one or more additional substances, such as non-ionic molecules, eutectic molecules and / or solvent molecules.

[0021] "Alkyl" refers to an unbranched or branched saturated hydrocarbon chain. For example, an alkyl group may have 1 to 6 carbon atoms (i.e., a C1-C6 alkyl group). Examples of suitable alkyl groups include, but are not limited to, methyl (Me, CH3), ethyl (Et, -CH2CH3), 1-propyl (n-Pr, n-propyl, -CH2CH2CH3), 2-propyl (i-Pr, i-propyl, -CH(CH3)2), 1-butyl (n-Bu, n-butyl, -CH2CH2CH2CH3), 2-methyl-1-propyl (i-Bu, i-butyl, -CH2CH(CH3)2), 2-butyl (s- Bu,s-butyl,-CH(CH3)CH2CH3), 2-methyl-2-propyl (t-Bu,t-butyl,-C(CH3)3), 1-pentyl (n-pentyl,-CH2CH2CH2CH2CH3), 2-pentyl (CH(CH3)CH2CH2CH3), 3-pentyl (-CH(CH2CH3)2), 2-methyl-2-butyl (-C(CH3)2CH2CH3), 3-methyl-2-butyl (-CH(CH3)CH (CH3)2), 3-methyl-1-butyl (-CH2CH2CH(CH3)2), 2-methyl-1-butyl (-CH2CH(CH3)CH2CH3), 1-hexyl (-CH2CH2CH2CH2CH2CH3), 2-hexyl (-CH(CH3)CH2CH2CH2CH3), 3-hexyl (-CH(CH2CH3)(CH2CH2CH3)), 2-methyl-2-pentyl (-C(CH3)2CH2CH2CH3), 3-methyl -2-pentyl (-CH(CH3)CH(CH3)CH2CH3), 4-methyl-2-pentyl (-CH(CH3)CH2CH(CH3)2), 3-methyl-3-pentyl (-C(CH3)(CH2CH3)2), 2-methyl-3-pentyl (-CH(CH2CH3)CH(CH3)2), 2,3-dimethyl-2-butyl (-C(CH3)2CH(CH3)2) and 3,3-dimethyl-2-butyl (-CH(CH3)C(CH3)3).

[0022] "Cycloalkyl" generally refers to a cycloalkyl group containing 3 to 8 carbon atoms, including cyclopropyl (-C3H7), cyclobutyl (-C4H9), cyclopentyl (-C5H11), cyclohexyl (-C6H11) or their "optional substituents".

[0023] "Aryl" refers to an aromatic hydrocarbon radical derived by removing a hydrogen atom from a single carbon atom of a parent aromatic ring system. For example, an aryl group can have 6 to 20 carbon atoms, 6 to 14 carbon atoms, or 6 to 10 carbon atoms. Typical aryl groups include, but are not limited to, radicals derived from benzene (e.g., phenyl), as well as phenyl, naphthyl, anthracenyl, biphenyl, and the like.

[0024] The term "optionally substituted" when referring to a particular moiety of a compound of Formula I (eg, optionally substituted phenyl) refers to that moiety wherein all substituents are hydrogen or wherein one or more hydrogens of the moiety may be replaced with a recited substituent.

[0025] Certain commonly used alternative chemical names may or may not be used. For example, a divalent group such as a divalent "alkyl" group, a divalent "aryl" group, a divalent "cycloalkyl" group, etc., may also be referred to as an "alkylene" group or an "alkenyl" group or an alkyl group; an "arylene" group or an "alkenyl" group or an aryl group; a "cycloalkylene" group or a "cycloalkylenyl" group or a cycloalkyl group.

[0026] As used herein, the term "treat", unless otherwise indicated, refers to reversing, alleviating, inhibiting or preventing the progression of the disorder or condition to which the term applies, or one or more symptoms of the disorder or condition. As used herein, the term "treating" refers to the act of treating, and "treating" is clearly defined above.

[0027] As used herein, the term "therapeutically effective amount" (or "pharmaceutically effective amount") is the amount of a compound of Formula I present in a composition described herein that is necessary to provide the desired levels of drug in the secretions and tissues of the airways and lungs, or in the blood of a subject to be treated to give the desired physiological response or desired biological effect when such composition is administered by a selected route of administration. The exact amount will depend on many factors, such as the specific compound of Formula I, the specific activity of the composition, the delivery device employed, the physical properties of the composition, its intended use, and patient considerations such as the severity of the disease state, patient cooperation, and can be quickly determined by one skilled in the art based on the information provided herein.

[0028] Compound

[0029] Provided herein are compounds of Formula I:

[0030]

[0031] or a pharmaceutically acceptable salt, wherein:

[0032] Each R1 and R2 is independently H, or C1-C6 alkyl, 3-8 membered cycloalkyl or aryl, or an optional substituent thereof;

[0033] m is an integer greater than 1; n is an integer greater than or equal to 0.

[0034] In some embodiments, wherein R1 and m are defined as in Formula I, R2 = H, n = 0; that is, the compound of Formula I is a compound having Formula Ia:

[0035]

[0036] In some embodiments, wherein R1=CH3, m=2, R2=H, n=0 in Formula I, that is, the compound of Formula I has the following structure:

[0037]

[0038] In some embodiments, in Formula I, R1=CH3, m=4, R2=H, n=0; that is, the structure of the compound of Formula I is as follows:

[0039]

[0040] In some embodiments, in Formula I, R1=R2, m=n; the compound of Formula I is a compound having Formula Ib:

[0041]

[0042] In some embodiments, in Formula I, R1=R2=CH3, m=n=2, that is, Formula I has the following structure:

[0043]

[0044] A pharmaceutical preparation comprising a pharmaceutically effective amount of a compound or a pharmaceutically acceptable salt thereof as described in any of the above technical solutions. In some embodiments, the pharmaceutical preparation is for subcutaneous administration, intravenous administration, oral administration or inhalation administration.

[0045] In other embodiments, the pharmaceutical preparation is a granule, capsule, tablet, pill, injection preparation, suspension preparation, solution preparation, inhalant such as aerosol, powder spray, spray, etc.

[0046] A use of the compound described in any one of the above technical solutions or a pharmaceutically acceptable salt thereof in the preparation of a drug for treating or preventing viral infection in humans or animals.

[0047] The compound is administered to humans or animals orally, intravenously, subcutaneously or by inhalation.

[0048] The viral infection is a coronavirus infection.

[0049] Furthermore, the animal is a feline. Furthermore, the animal is a cat.

[0050] Furthermore, the viral infection is feline infectious peritonitis virus (FIPV) infection. The compound of the present invention can effectively inhibit feline infectious peritonitis virus (FIPV) infection and treat feline infectious peritonitis.

[0051] A method for preparing the compound described in any one of the above technical solutions, comprising:

[0052] (I) Prepare the intermediate int-1 with the following structure:

[0053]

[0054] (ii) Synthesizing PEGylated phosphoric acid or its corresponding salt having the following structure:

[0055]

[0056] (III) Reaction of the intermediate with pegylated phosphoric acid or its corresponding salt to obtain the following compound:

[0057]

[0058] (IV) removing the protecting group to obtain the following compound:

[0059]

[0060] Taking PEGylated phosphoric acid as an example, the reaction equation is as follows:

[0061]

[0062] In some embodiments, the preparation method of compound int-1 is as shown in the following formula:

[0063]

[0064] The steps include:

[0065] (1) Compound 1 is mixed with 2,2-dimethoxypropane and TsOH in an organic solvent I (such as acetone), stirred for 20 to 60 minutes, and isopropyl acetate is slowly added; the resulting mixture is filtered, washed with 2:1 heptane / isopropyl acetate, and dried under vacuum (30 to 50° C.) to obtain Compound 2;

[0066] (2) Compound 2 is mixed with K2CO3 solution and organic solvent II (such as ethyl acetate), and the layers are separated; the organic layer is washed with water and concentrated to a set volume; isopropyl acetate is added again and concentrated; the flask is refilled with isopropyl acetate and concentrated; heptane is slowly added to the viscous mixture; the resulting mixture is filtered and washed with 2:1 heptane / isopropyl acetate; and vacuum dried (30-50°C) to obtain compound 3; compound 3 is named compound Int-1.

[0067] Further, the method for synthesizing the PEGylated phosphoric acid prodrug compound (single substitution, n=0) of the above structure is shown in the following formula:

[0068]

[0069] Add POCl3 to anhydrous MeCN; replace with nitrogen, and add compound 101-1 dropwise at 0°C; raise the reaction mixture to room temperature and stir to complete the reaction; add water to the solution, heat at 50-60°C, and protect with N2 at the same time, and react for 1.5-3h; dry and purify in high vacuum to obtain compound 101-2;

[0070] Compound Int-1, DCC and DMAP were added to a solution of compound 101-2 in anhydrous pyridine (9.5 mL); the reaction mixture was stirred at room temperature for 10 to 20 hours, and post-treated to obtain compound 101-3;

[0071] HCl was added to the THF solution of compound 101-3; the reaction mixture was stirred at room temperature for 1 to 3 hours, and post-treated to obtain compound JWY-101.

[0072] Further, the method for synthesizing the PEGylated phosphoric acid prodrug compound of the above structure (disubstituted, m≠0, n≠0) is shown in the following formula:

[0073]

[0074] The steps include:

[0075] At -5 to 5°C, compound 102-1 was added to a THF solution containing NaH; at 0°C, a THF solution containing POCl3 was added and stirred at room temperature for 20 to 60 minutes; then the reaction mixture was stirred at room temperature for 10 to 20 hours, and post-treated to obtain compound 102-2;

[0076] The solution of DMAP and compound 102-2 was added to the DCM solution of Int-1 at 0°C; the reaction mixture was stirred at room temperature for 10 to 20 hours, and post-treated to obtain compound 102-3;

[0077] At -5 to 5°C, HCl was added to a THF (0.8 mL) solution of compound 102-3; the reaction mixture was stirred at room temperature for 1 to 3 hours, and post-treated to obtain JWY-102.

[0078] The embodiments of the present application are not limited to any composition and method, which can be changed and understood by the technician. In order to more easily understand the present disclosure, some terms are first defined. Unless otherwise defined, all technical and scientific terms used herein have the same meanings that are generally understood by those of ordinary skill in the art to which the embodiments of the present disclosure are related. Many similar, modified or equivalent methods and materials described herein can be used in the practice of the embodiments of the present disclosure without the need for unnecessary experiments. Preferred materials and methods are described herein. When describing and requiring embodiments of the present disclosure, the following terms will be used according to the definitions listed below.

[0079] Compared with the prior art, the beneficial effects of the present invention are as follows:

[0080] The present invention innovatively synthesizes a new PEGylated phosphoric acid prodrug compound molecule, and the raw materials of the synthesis route are easily available, the reaction conditions are mild, the operation is simple, the cost is low, and it is suitable for subsequent research and production. The innovative compound and the composition thereof of the present invention can be used to treat or prevent viral infections in humans or animals. The compound and the composition thereof can effectively inhibit feline infectious peritonitis virus (FIPV) infection and treat feline infectious peritonitis. BRIEF DESCRIPTION OF THE DRAWINGS

[0081] Figure 1 It is the result of CPE (cytopathic effect test);

[0082] Figure 2 This is the result of cell pathological changes after FIPV infection;

[0083] Figure 3 For cytotoxicity assay (CC 50 Determination) results;

[0084] Figure 4 For EC 50 Measurement results;

[0085] Figure 5 This is the average concentration-time curve of JWY-101 in plasma after subcutaneous administration of JWY-101 to SD rats.

[0086] Figure 6 This is the average concentration-time curve of JWY-103 in plasma after subcutaneous administration of JWY-101 in SD rats.

[0087] Figure 7 This is the average concentration-time curve of JWY-101 in plasma after subcutaneous administration of JWY-101 to kittens.

[0088] Figure 8 This is the average concentration-time curve of JWY-101 in plasma after subcutaneous administration of 5 mg / kg JWY-101 to adult cats.

[0089] Fig. 9 This is the average concentration-time curve of JWY-101 in plasma after oral administration of 10 mg / kg JWY-101 to adult cats.

[0090] Fig.10 This is the white-globulin ratio curve of the medium-dose group, i.e., sick cats were subcutaneously administered 5 mg / kg JWY-101.

[0091] Fig.11 This is the white-globulin ratio curve of the high-dose group, i.e., sick cats were subcutaneously administered 7 mg / kg JWY-101. DETAILED DESCRIPTION

[0092] The present invention is further illustrated by the following examples, which should not be considered as limiting in any way. Embodiments of the present invention are further defined in the following non-limiting examples. It should be understood that these embodiments, although representing certain embodiments of the present invention, are given by way of example only. From the above discussion and these embodiments, those skilled in the art can determine the essential features of the present invention, and without departing from its features and scope, various changes and modifications can be made to the embodiments of the present invention to adapt them to various usages and conditions. Therefore, in addition to the embodiments shown and described herein, various modifications of the embodiments of the present invention will be feasible for those skilled in the art from the above description. Such modifications also fall within the scope of the appended claims.

[0093] Chemical substances

[0094] All compounds were purchased from Sigma-Aldrich without further purification.

[0095] Analytical methods

[0096] NMR spectroscopy

[0097] In general, the structures of the final products of the salts were determined by nuclear magnetic resonance (NMR) spectroscopy. Proton NMR spectroscopy was performed using a Bruker Advance 500 (500 MHz) and the NMR chemical shift values ​​are reported in ppm. Unless otherwise stated, proton NMR measurements were performed at ambient temperature; the following abbreviations have been used to characterize NMR peaks: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; dd, doublet of doublets; ddd, doublet of doublets; dt, doublet of triplets; bs, broad signal. The chemical shifts (δ) of the NMR peaks are reported in parts per million (ppm) of tetramethylsilane (TMS) and are referenced to the respective residual undeuterated solvent peaks: CDCl3 = 7.26 ppm, MeOH-d4 = 3.31 ppm (1H-NMR). The coupling constants (J) are expressed in Hz.

[0098] Example 1: Synthesis of intermediate compound (Compound Int-1)

[0099] 1.1 Preparation of compound 2

[0100]

[0101] A mixture of compound 1 (1 g, 3.43 mmol, 1.0 equiv.) and 2,2-dimethoxypropane (2.1 mL, 17.2 mmol, 5.0 equiv.) in acetone (5 mL) was added with TsOH (649 mg, 3.77 mmol, 1.1 equiv.) at room temperature. After stirring for 30 minutes, isopropyl acetate (5 ml) was slowly added. The resulting mixture was filtered and the filtrate was washed with 2:1 heptane / isopropyl acetate (5 ml). Compound 2 (800 mg, 46.3%) was obtained by vacuum drying at 40°C.

[0102] 1.2 Preparation of compound 3

[0103]

[0104] Compound 2 (800 mg, 1.59 mmol, 1.0 equiv.) was added to a flask, and 5% K2CO3 aqueous solution (10 ml) and ethyl acetate (10 ml) were added. The layers were separated, and the aqueous layer was extracted with ethyl acetate. The organic layer was washed with water and concentrated to about 5 ml. Isopropyl acetate (5 ml) was added back to the flask and concentrated to about 5 ml. Isopropyl acetate (5 ml) was refilled into the flask and concentrated to 5 ml. Heptane (5 ml) was slowly added to the viscous mixture. The resulting mixture was filtered and washed with 2:1 heptane / isopropyl acetate (5 ml). Compound 3 (650 mg) was obtained by vacuum drying at 40°C. Compound 3 was named Compound Int-1, and JWY-101 and JWY-102 were synthesized by the following steps.

[0105] Example 2: Synthesis of JWY-101

[0106]

[0107] 1.1 Preparation of Compound 101-2

[0108]

[0109] Anhydrous MeCN (40 mL) was added to a dry flask, and POCl3 (0.38 mL, 4.16 mmol, 0.5 equiv.) was added via a syringe. Nitrogen was evacuated in the flask. Compound 101-1 (1.0 g, 8.32 mmol, 1.0 equiv.) was added dropwise to the solution at 0°C. The reaction mixture was raised to room temperature and stirred overnight. Water (20 ml) was added to the solution, heated at 55°C while protecting with N2, and reacted for 2 h. The remaining residue was dried in a high vacuum overnight. Compound 101-2 (300 mg, 11.9%) was purified by column chromatography (DCM: ethanol: water = 60:30:5) as a colorless oily liquid. (LCMS (ESI) [M+1] + =201.3)

[0110] 1.2 Preparation of compound 101-3

[0111]

[0112] Compound Int-1 (1.2 g, 3.6 mmol, 1.0 equiv), DCC (760 mg, 3.6 mmol, 1 equiv) and DMAP (44 mg, 0.36 mmol, 0.1 equiv) were added to a solution of compound 101-2 (736 mg, 3.6 mmol, 1 equiv) in anhydrous pyridine (9.5 mL). The reaction mixture was stirred at room temperature for 16 hours. LCMS showed that the reaction was complete. The reaction mixture was concentrated under reduced pressure to obtain a crude product, which was purified by preparative high performance liquid chromatography to obtain compound 101-3 (71 mg, 3.76%). (LCMS (ESI) [M+1] + =514.3)

[0113] 1.3 Preparation of JWY-101

[0114]

[0115] HCl (1N, 1 ml) was added to a solution of compound 101-3 (71 mg, 0.14 mmol) in THF (3 ml). The reaction mixture was stirred at room temperature for 2 hours. LCMS showed that the reaction was complete. The reaction mixture was concentrated under reduced pressure to obtain a crude product, which was purified by preparative HPLC to obtain JWY-101 (17.8 mg, 26.9%).

[0116] LCMS(ESI)[M+1] + =474.3. 1 H NMR (400MHz, MeOD) δ8.06 (s, 1H), 7.30 (d, J=

[0117] 4.8Hz,1H),7.13(d,J=4.8Hz,1H),4.77(d,J=5.3Hz,1H),4.40–4.32(m,1H),4.28–4.19(m,2 H),4.17–4.09(m,1H),4.03–3.94(m,2H),3.67–3.58(m,4H),3.54–3.48(m,2H),3.32(s,3H).

[0118] Example 3: Synthesis of JWY-102

[0119]

[0120] 1.1 Preparation of compound 102-2

[0121]

[0122] Compound 102-1 (1.14 g, 9.5 mmol, 1.0 equiv) was added to a THF (14 mL) solution containing NaH (380 mg, 9.5 mmol, 1.0 equiv) at 0°C. A THF (10 mL) solution containing POCl3 (1.5 g, 9.8 mmol, 1.0 equiv) was added at 0°C and stirred at room temperature for 0.5 h. The reaction mixture was then stirred at room temperature for 3 hours. The solvent was removed in vacuo to give compound 102-2, which was used in the next step.

[0123] 1.2 Preparation of compound 102-3

[0124]

[0125] DMAP (24 mg, 0.2 mmol, 0.1 equiv) and a solution of compound 102-2 (0.25 M, DCM, 8 mL, 2 mmol, 1.0 equiv) were added to a DCM solution (6 mL) of compound Int-1 (660 mg, 2 mmol, 1.0 equiv) at 0°C. The reaction mixture was stirred at room temperature for 16 hours. LCMS showed that the reaction was complete. The solvent was removed in vacuo and purified by preparative HPLC to give compound 102-3 (48 mg, 3.9%). (LCMS (ESI) [M+1] + =616.4)

[0126] 1.3 Preparation of JWY-102

[0127]

[0128] At 0°C, HCl (1N, 0.8 mL) was added to a solution of compound 102-3 (48 mg, 0.078 mmol, 1.0 equiv) in THF (0.8 mL). The reaction mixture was stirred at room temperature for 2 hours. LCMS showed that the reaction was complete. The solvent was removed in vacuo and purified by preparative HPLC to obtain JWY-102 (10.3 mg, 23.1%).

[0129] LCMS(ESI)[M+1] + =576.4. 1 H NMR (400MHz, MeOD) δ7.89 (s, 1H), 6.95 (d, J=

[0130] 4.6Hz,1H),6.91(d,J=4.6Hz,1H),4.97–4.87(m,1H),4.43–4.35(m,2H),4.34–4.26(m,1H),4.21 (t,J=5.6Hz,1H),4.18–4.11(m,4H),3.66–3.57(m,8H),3.54–3.48(m,4H),3.33(d,J=3.4Hz,6H).

[0131] Example 4: Inhibition of Feline Infectious Peritonitis Virus (FIPV) Infection

[0132] CRFK (Crandell-Rees feline kidney) cells were pre-incubated with the test compounds and then infected with FIPV at an MOI of 0.01. The plates were incubated for 24 h and each well was tested for infection-induced phenotypic changes.

[0133] CPE (cytopathic effect test) results are shown in Figure 1 . Figure 1 The cell images in the figure are all magnified 100 times. From the results, we can see that when the drug concentration is 0μM, that is, when there is no drug effect, most of the cells in the wells show pathological changes after FIPV infection, and the cells shrink, stack, die and fall off, and a large blank area appears at the bottom of the wells; while the positive control compound GS-441524 completely prevents FIPV-induced pathological changes at 10μM, and the cell morphology in the wells is no different from that of normal cells; compounds JWY-101 and JWY-102 show similar activity to GS-441524.

[0134] We used cell analysis software based on well plate imaging to quantitatively evaluate the cell morphological pathological changes of FIPV-infected cells (GS-441524, JWY-101, and untreated control group) and healthy cells, and performed 6 parallel experiments at the same time. Figure 2 The results show the percentage of cells with pathological changes in each group. Among them, the cells in the untreated negative control group showed significant pathological changes after FIPV infection, with 80-100% of the cells showing pathological changes; 0-20% of the cells in the JWY-101 and GS-441524 groups showed pathological changes; and 0% of the healthy cells showed pathological changes. The results showed that JWY-101 can effectively inhibit the pathological changes of FIPV-infected cells, and the effect is equivalent to GS-441524.

[0135] Example 5: Cytotoxicity and in vitro anti-FIPV activity assay of compounds JWY-101 and JWY-102

[0136] 1Drug dilution method

[0137] 1) Dissolution: Add DMSO and dissolve by pipetting and mix, see Table 1:

[0138] Table 1

[0139] drug Molecular weight Mass / mg DMSO / μL Final concentration / mM JWY-101 473.38 11.7 247.16 100 JWY-102 575.51 11.2 194.61 100

[0140] 2) Filter using a 0.22 μm filter

[0141] 2CC 50 Determination

[0142] 1) Cell plating: CRFK cells were seeded in a 96-well plate and incubated at 37°C for 24 h. The number of cells was approximately 2×10 4 Pieces / hole.

[0143] 2) Drug dilution: Take 10 sterilized 1.5 mL centrifuge tubes and press 1 # ~10 # Number them in sequence, from 1 # Add 990 μL of culture medium containing 3% FBS to the tube from # Add 900 μL of culture medium containing 3% FBS to each tube. Add 10 μL of 100 mM JWY101 / 102 solution to tube 1, vortex for 15 seconds, then aspirate 100 μL and add 2 # Tube, dilute the drug to 9 times # Tube #10 was added with culture medium containing 1% DMSO and 3% FBS as solvent control.

[0144] 3) Cell washing: Use an 8-channel pipette to remove the culture medium in the 96-well plate and wash twice with PBS.

[0145] 4) Add drugs: 100 μL of the diluted drug solution was added to each well from right to left in the order from low to high to the 9th to 1st column, 100 μL of culture medium containing 1% DMSO and 3% FBS was added to the 10th column, and 100 μL of culture medium containing 3% FBS was added to the 11th column. The 96-well plate was placed in an incubator (37°C, containing 5% CO2), incubated for 24 hours, and the cell condition was observed.

[0146] 5) Cell activity detection: 10 μL CCK8 was added to each well, and the absorbance at 450 nm was read using a microplate reader after incubation for 1 h. The results were entered into Excel and then imported into GraphPad Prime 9 for analysis.

[0147] 6) Cell activity calculation formula: A is the absorbance of the sample at 450 nm.

[0148] 3EC 50 Determination

[0149] 1) Cell plating: CRFK cells were seeded in a 96-well plate and incubated at 37°C for 24 h. The number of cells was approximately 2×10 4 Pieces / hole.

[0150] 2) Sample preparation

[0151] a) Drug dilution: culture medium containing 3% FBS and 10, 6, 5, 2, 1, 0.75 and 0.5 μM JWY-101 and JWY-102 was prepared respectively.

[0152] b) Virus dilution: dilute the virus to 10 3.0 TCID 50 / mL.

[0153] 3) Virus inoculation: Add 100 μL of serum-free culture medium to each well in column 10 of a 96-well plate, and add 100 μL of virus dilution solution to each well in columns 1-9, and incubate at 37° C. for 1 h.

[0154] 4) Medium change: Aspirate the liquid in each well and replace it with culture medium containing 3% FBS and different concentrations of drugs. Incubate at 37°C for 24 hours and observe the cytopathic effect.

[0155] 5) Result determination: Collect the supernatant from each well, mix the wells with the same drug concentration in the same group and determine the TCID 50 (Reed-Muench method), and the data were imported into GraphPad Prime 9 to obtain the results.

[0156] 4The results are as follows:

[0157] 1) Cytotoxicity assay (CC) 50 The results of the determination are shown in Figure 3 .

[0158] CC 50 The half toxic concentration refers to the drug concentration at which 50% of the host cells are destroyed in an in vitro test. Figure 3 The results show that the CC of JWY-101 and JWY-102 50 The measured values ​​were all above 100 μM, and the cytotoxicity was low.

[0159] 2) In vitro anti-FIPV activity assay (EC 50 The results of the determination are shown in Figure 4 .

[0160] EC 50 The half effective concentration refers to the drug concentration at which 50% of virus-infected cells are inhibited by the drug in an in vitro test. Figure 4 The results show that the EC of JWY-101, JWY-102 and GS-44152450 The measured values ​​were 0.6653μM, 0.8315μM and 0.6384μM respectively. Both JWY-101 and JWY-102 can achieve effective inhibition at low drug concentrations, and the inhibitory effect of JWY-101 is comparable to that of GS-441524.

[0161] Example 6: The compound JWY-101 synthesized in Example 2 was subjected to the following pharmacokinetic test. (I) This experiment investigated the pharmacokinetic behavior characteristics of JWY-101 and its metabolite JWY-103 in SD rats under the condition of subcutaneous administration of JWY-101.

[0162] 1. Sample configuration and preparation

[0163] (1) Synthesis of intermediate metabolite JWY-103

[0164] Due to the requirements of the experimental analysis method, the intermediate metabolite JWY-103 was also synthesized.

[0165] The method for synthesizing the structure is shown below:

[0166]

[0167] The synthesis steps are as follows: Compound 103-1 is weighed into a Schlenk bottle, and ultra-dry THF, triethylamine and POCl3 are added under a nitrogen atmosphere, and the mixture is reacted at room temperature for 3 hours, and then separated by column chromatography to obtain compound 2. The clean compound 103-2 is transferred to a round-bottom flask, and THF and 4N HCl are added to react at room temperature. The reaction is completed when the raw material point of compound 2 disappears under TLC monitoring, and compound JWY-103 is obtained after post-treatment.

[0168] (2) Preparation of test samples

[0169] The test article was prepared to a final concentration of 2 mg / mL for subcutaneous administration.

[0170] The test sample was prepared with DMSO, which was diluted to the final concentration with PBS. After preparation, JWY-101 was a colorless and transparent liquid.

[0171] 2. Experimental system

[0172] (1) Experimental animals

[0173] Species & strain: SD rat

[0174] Source of experimental animals: Spike (Beijing) Biotechnology Co., Ltd.

[0175] Planned age at dosing: 6-8 weeks at the start of dosing.

[0176] Planned body weight at dosing: 180-250 g at the start of dosing.

[0177] Number of animals and gender: 4, male, 1 of which was a spare rat.

[0178] (2) Feeding and management

[0179] The animals were housed in transparent resin plastic cages (530 mm x 400 mm x 200 mm).

[0180] Fluorescent lighting, 12 hours of lighting (08:00-20:00) and 12 hours of no lighting per day. Dark time can be interrupted intermittently due to the needs of research-related activities. The ambient temperature and relative humidity of the animal room should be controlled within the range of 20-26°C and 40-70%, respectively, and monitored and recorded daily.

[0181] The diet is a certified rodent diet. The batch number of the diet will be recorded in the study records.

[0182] Drinking water was filtered and sterilized by an ultrapure water machine. All animals had free access to drinking water during the experiment.

[0183] (3) Animal marking

[0184] Use a high-quality marker pen to write the number directly on the mouse's tail and use basic fuchsin to mark the back. Attach a label to the outside of the animal cage to mark the study number, animal number, group number, gender and other information.

[0185] 3. Brief description of experimental methods

[0186] (1) Groups and doses

[0187] No random grouping was performed. The weight of the animals was measured before administration, and healthy animals with similar weight were selected for inclusion in the experiment (see Table 2).

[0188] Table 2

[0189]

[0190] *During the experiment, if an unexpected situation occurs during the administration, the blank group animals can be used to replace them in time. After the experiment, the blank group animals will be used to collect blank samples.

[0191] Dosing frequency: Single dose.

[0192] (2) Sample collection

[0193] After ether anesthesia, at least 0.2 mL of blood was collected from the jugular vein and anticoagulant: sodium heparin was added.

[0194] Collection time: 30 minutes before administration, and 5 minutes, 15 minutes, 30 minutes, 1 hour, 1.5 hours, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, and 24 hours after administration.

[0195] (3) Sample processing

[0196] After blood samples were collected, they were placed in labeled centrifuge tubes and rapidly centrifuged to separate plasma. The centrifugation conditions were: 3000 rpm, 15 minutes, 4°C. The plasma was stored at below -80°C for testing.

[0197] 4. Standard curve and quality control samples

[0198] (1) Preparation of JWY-101, JWY-103 standard curve and quality control samples: Prepare standard curve working solution and quality control working solution using 50% methanol water as diluent. Take 5 μL of each working solution and mix with 45 μL of blank plasma to prepare plasma standard curve and quality control samples. Add 250 μL of internal standard working solution (200 g / mL, methanol, methyldopa) to the prepared standard curve and quality control samples, vortex mix for 1 min, and centrifuge at 4°C, 15400g for 10 min. Take the supernatant for sampling and analysis.

[0199] (2) Sample pretreatment

[0200] Plasma sample pretreatment: After the plasma samples were thawed at room temperature, 40 μL was taken, 200 μL of internal standard (200 ng / mL, methanol, methyldopa) was added, vortexed for about 1 min, centrifuged at 4°C, 15400g for 10 min, and the supernatant was taken for sampling and analysis.

[0201] 5. Data collection and statistical analysis

[0202] Analyst 1.6.3 software outputs original spectra, concentration, accuracy and other data.

[0203] Microsoft Excel 2007 software was used to calculate the mean, standard deviation, coefficient of variation, etc.

[0204] WinNonlin software non-compartmental model method (NCA) was used to perform AUC and C max ,t 1 / 2 Calculation of main pharmacokinetic parameters.

[0205] CT plots were performed using GraphPad Prism 9.

[0206] Specific steps:

[0207] Four SD rats with similar body weight were selected for the experiment. Rats 1-3 were subcutaneously administered JWY-101 at a dose of 4 mg / kg, a single dose. Blood was collected 30 minutes before administration and at 5 minutes, 15 minutes, 30 minutes, 1 hour, 1.5 hours, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, and 24 hours after administration. The remaining rats were used as a spare group for standby and blank matrix collection. The LC-MS / MS analysis method was used to detect the content of JWY-101 and JWY-103 in plasma, and the quantitative limit of the method was 4 ng / mL. The plasma concentration data were statistically analyzed using the metabolic kinetic data analysis software WinNonlin 7.0, and the pharmacokinetic parameters were calculated using the non-compartmental model method (NCA).

[0208] The main pharmacokinetic parameters of JWY-101 in SD rats after administration are shown in Table 3:

[0209] Table 3 Main pharmacokinetic parameters of JWY-101 in SD rats after administration

[0210]

[0211] The average concentration-time curve of JWY-101 and JWY-103 in plasma after subcutaneous administration of JWY-101 in SD rats is shown in Figure 5 , Figure 6 .

[0212] Conclusion: Subcutaneous administration of 4 mg / kg JWY-101, SD rat plasma JWY-101, t 1 / 2 The average value is 0.265 h, C max The mean value was 3740 ng / mL, AUC 0-t The mean value was 1522 g·h / mL; rat plasma JWY-103, t 1 / 2 The average value is 0.241 h, C max The mean value was 80.7 ng / mL, AUC 0-t The average value is 32.6 g·h / mL. Figure 5-6 The results show that in the JWY-101 administration group, a large amount of prodrug JWY-101 prototype components and a certain amount of ester bond cleavage metabolite JWY-103 can be detected in rat plasma at the same time. The same peak time of JWY-101 and JWY-103 indicates that the ester bond of the prodrug breaks rapidly in the systemic circulation. The data results show that JWY-101 can effectively enter the rat systemic circulation after administration, and the ester bond breaks in the systemic circulation in a short time to produce the metabolite JWY-103.

[0213] (II) This experiment investigated the pharmacokinetic behavior of JWY-101 in cats (kittens) under the condition of subcutaneous administration of JWY-101.

[0214] 1. Preparation of test samples

[0215] The test sample was prepared to a final concentration of 5 mg / mL for the preparation of working solution.

[0216] The test sample was prepared with DMSO, which was diluted to the final concentration with 50% methanol water. It was a colorless and transparent liquid after preparation.

[0217] 2. Experimental Animals

[0218] Species & strain: Cat (about 600g).

[0219] 3. Brief description of experimental methods

[0220] (1) Groups and doses

[0221] No random grouping was performed. The weight of the animals was measured before administration, and healthy animals with similar weight were selected for inclusion in the experiment (see Table 5).

[0222] Table 4 Experimental animal grouping table

[0223]

[0224] *During the experiment, if an unexpected situation occurs during the administration, the blank group animals can be used to replace them in time. After the experiment, the blank group animals will be used to collect blank samples.

[0225] Dosing frequency: Single dose.

[0226] (2) Sample collection

[0227] After ether anesthesia, at least 0.2 mL of blood was collected from the jugular vein and anticoagulant: sodium heparin was added.

[0228] Collection time: 30 minutes before administration, and 5 minutes, 15 minutes, 30 minutes, 1 hour, 1.5 hours, and 2 hours after administration.

[0229] (3) Sample processing

[0230] After blood samples were collected, they were placed in labeled centrifuge tubes and rapidly centrifuged to separate plasma. The centrifugation conditions were: 3000 rpm, 15 minutes, 4°C. The plasma was stored at below -80°C for testing.

[0231] 4. Standard curve and quality control samples

[0232] (1) Preparation of JWY-101 standard curve and quality control samples: Prepare the standard curve working solution and quality control working solution using 50% methanol water as the diluent. Take 5 μL of each working solution and mix it with 45 μL of blank plasma to prepare the plasma standard curve and quality control samples. Add 250 μL of internal standard working solution (200 g / mL, methanol, methyldopa) to the prepared standard curve and quality control samples, vortex mix for 1 min, and centrifuge at 4°C and 15400g for 10 min. Take the supernatant for sampling and analysis.

[0233] (2) Sample pretreatment

[0234] Plasma sample pretreatment: After the plasma samples were thawed at room temperature, 40 μL was taken, 200 μL of internal standard (200 ng / mL, methanol, methyldopa) was added, vortexed for about 1 min, centrifuged at 4°C, 15400g for 10 min, and the supernatant was taken for sampling and analysis.

[0235] 5. Data collection and statistical analysis

[0236] Analyst 1.6.3 software outputs original spectra, concentration, accuracy and other data.

[0237] Microsoft Excel 2007 software was used to calculate the mean, standard deviation, coefficient of variation, etc.

[0238] WinNonlin software non-compartmental model method (NCA) was used to perform AUC and C max ,t 1 / 2 Calculation of main pharmacokinetic parameters.

[0239] CT plots were performed using GraphPad Prism 9.

[0240] 6. Experimental steps

[0241] Four cats of similar weight were selected for the experiment and divided into two groups. Cats 1-3 were subcutaneously administered JWY-101 at a dose of 5 mg / kg, a single dose. Blood was collected 30 minutes before administration and at 5 minutes, 15 minutes, 30 minutes, 1 hour, 1.5 hours, and 2 hours after administration. The remaining cats were grouped as group 2 as a backup group for backup and blank matrix collection. The LC-MS / MS analysis method was used to detect the content of JWY-101 and GS441524 in plasma, and the quantitative limit of the method was 4 ng / mL. The plasma concentration data were statistically analyzed using the metabolic kinetic data analysis software WinNonlin 7.0, and the pharmacokinetic parameters were calculated using the non-compartmental model method (NCA).

[0242] The main pharmacokinetic parameters of JWY-101 in cats after administration are shown in Table 5:

[0243] Table 5 Main pharmacokinetic parameters of JWY-101 in cats after administration

[0244]

[0245] The mean concentration-time curve of JWY-101 in plasma after subcutaneous administration of 5 mg / kg JWY-101 to cats is shown in Figure 7 .

[0246] 7. Experimental summary

[0247] In the JWY-101 administration group, a large amount of prodrug JWY-101 was detected in the cat plasma. The data results showed that JWY-101 could effectively enter the systemic circulation of experimental kittens after administration.

[0248] (III) This experiment investigated the pharmacokinetic behavior of JWY-101 in experimental cats (adult cats) under the condition of subcutaneous administration of JWY-101.

[0249] 1. Preparation of test samples

[0250] The test sample was prepared to a final concentration of 5 mg / mL for the preparation of working solution.

[0251] The test sample was prepared with DMSO, which was diluted to the final concentration with 50% methanol water. It was a colorless and transparent liquid after preparation.

[0252] 2. Experimental Animals

[0253] Species & Strain: Cat (approximately 2.5 kg).

[0254] 3. Brief description of experimental methods

[0255] (1) Groups and doses

[0256] No random grouping was performed. The weight of the animals was measured before administration, and healthy animals with similar weight were selected for inclusion in the experiment, see Table 8.

[0257] Table 6 Experimental animal grouping table

[0258]

[0259]

[0260] *During the experiment, if an unexpected situation occurs during the administration, the blank group animals can be used to replace them in time. After the experiment, the blank group animals will be used to collect blank samples.

[0261] Dosing frequency: Single dose.

[0262] (2) Sample collection

[0263] After ether anesthesia, at least 0.2 mL of blood was collected from the jugular vein and anticoagulant: sodium heparin was added.

[0264] Collection time: 30 minutes before administration, 5 minutes, 15 minutes, 30 minutes, 1 hour, 1.5 hours, 2 hours, 4 hours, 6 hours, 8 hours after administration,

[0265] 10h, 12h, 24h.

[0266] (3) Sample processing

[0267] After blood samples were collected, they were placed in labeled centrifuge tubes and rapidly centrifuged to separate plasma. The centrifugation conditions were: 3000 rpm, 15 minutes, 4°C. The plasma was stored at below -80°C for testing.

[0268] 4. Standard curve and quality control samples

[0269] (1) Preparation of JWY-101 standard curve and quality control samples: Prepare the standard curve working solution and quality control working solution using 50% methanol water as the diluent. Take 5 μL of each working solution and mix it with 45 μL of blank plasma to prepare the plasma standard curve and quality control samples. Add 250 μL of internal standard working solution (200 g / mL, methanol, methyldopa) to the prepared standard curve and quality control samples, vortex mix for 1 min, and centrifuge at 4°C and 15400g for 10 min. Take the supernatant for sampling and analysis.

[0270] (2) Sample pretreatment

[0271] Plasma sample pretreatment: After the plasma samples were thawed at room temperature, 40 μL was taken, 200 μL of internal standard (200 ng / mL, methanol, methyldopa) was added, vortexed for about 1 min, centrifuged at 4°C, 15400g for 10 min, and the supernatant was taken for sampling and analysis.

[0272] 5. Data collection and statistical analysis

[0273] Analyst 1.6.3 software outputs original spectra, concentration, accuracy and other data.

[0274] Microsoft Excel 2007 software was used to calculate the mean, standard deviation, coefficient of variation, etc.

[0275] WinNonlin software non-compartmental model method (NCA) was used to perform AUC and C max ,t 1 / 2 Calculation of main pharmacokinetic parameters.

[0276] CT plots were performed using GraphPad Prism 9.

[0277] 6. Experimental steps

[0278] Four cats of similar weight were selected for the experiment and divided into two groups. Cats 1-3 were subcutaneously administered JWY-101 at a dose of 5 mg / kg, a single dose. Blood was collected 30 minutes before administration and 5 minutes, 15 minutes, 30 minutes, 1 hour, 1.5 hours, 2 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, and 24 hours after administration. The remaining cats were grouped as group 2 as a spare group for standby and blank matrix collection. The LC-MS / MS analysis method was used to detect the content of JWY-101 and GS441524 in plasma, and the quantitative limit of the method was 4 ng / mL. The plasma concentration data were statistically analyzed using the metabolic kinetic data analysis software WinNonlin 7.0, and the pharmacokinetic parameters were calculated using the non-compartmental model method (NCA).

[0279] The main pharmacokinetic parameters of JWY-101 in cats after administration are shown in Table 7:

[0280] Table 7 Main pharmacokinetic parameters of JWY-101 in cats after administration

[0281]

[0282] The mean concentration-time curve of JWY-101 in plasma after subcutaneous administration of 5 mg / kg JWY-101 to cats is shown in Figure 8 .

[0283] 7. Experimental summary

[0284] In the JWY-101 administration group, a large amount of prodrug JWY-101 was detected in the cat plasma. The data results showed that JWY-101 could effectively enter the systemic circulation of experimental adult cats after administration.

[0285] (IV) This experiment investigated the pharmacokinetic behavior of JWY-101 in experimental cats (adult cats) under the condition of oral administration of JWY-101.

[0286] 1. Preparation of test samples

[0287] The test sample was prepared to a final concentration of 5 mg / mL for the preparation of working solution.

[0288] The test sample was prepared with DMSO, which was diluted to the final concentration with 50% methanol water. It was a colorless and transparent liquid after preparation.

[0289] 2. Experimental Animals

[0290] Species & Strain: Cat (approximately 3.5 kg).

[0291] 3. Brief description of experimental methods

[0292] (1) Groups and doses

[0293] No random grouping was performed. The weight of the animals was measured before administration, and healthy animals with similar weight were selected for inclusion in the experiment, see Table 8.

[0294] Table 8 Experimental animal grouping table

[0295]

[0296] Dosing frequency: Single dose.

[0297] (2) Sample collection

[0298] After ether anesthesia, at least 0.2 mL of blood was collected from the jugular vein and anticoagulant: sodium heparin was added.

[0299] Collection time: 30 minutes before administration, and 5 minutes, 10 minutes, 30 minutes, 1 hour, 1.5 hours, 2 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, and 24 hours after administration.

[0300] (3) Sample processing

[0301] After blood samples were collected, they were placed in labeled centrifuge tubes and rapidly centrifuged to separate plasma. The centrifugation conditions were: 3000 rpm, 15 minutes, 4°C. The plasma was stored at below -80°C for testing.

[0302] 4. Standard curve and quality control samples

[0303] (1) Preparation of JWY-101 standard curve and quality control samples: Prepare the standard curve working solution and quality control working solution using 50% methanol water as the diluent. Take 5 μL of each working solution and mix it with 45 μL of blank plasma to prepare the plasma standard curve and quality control samples. Add 250 μL of internal standard working solution (200 g / mL, methanol, methyldopa) to the prepared standard curve and quality control samples, vortex mix for 1 min, and centrifuge at 4°C and 15400g for 10 min. Take the supernatant for sampling and analysis.

[0304] (2) Sample pretreatment

[0305] Plasma sample pretreatment: After the plasma samples were thawed at room temperature, 40 μL was taken, 200 μL of internal standard (200 ng / mL, methanol, methyldopa) was added, vortexed for about 1 min, centrifuged at 4°C, 15400g for 10 min, and the supernatant was taken for sampling and analysis.

[0306] 5. Data collection and statistical analysis

[0307] Analyst 1.6.3 software outputs original spectra, concentration, accuracy and other data.

[0308] Microsoft Excel 2007 software was used to calculate the mean, standard deviation, coefficient of variation, etc.

[0309] WinNonlin software non-compartmental model method (NCA) was used to perform AUC and C max ,t 1 / 2 Calculation of main pharmacokinetic parameters.

[0310] CT plots were performed using GraphPad Prism 9.

[0311] 6. Experimental steps

[0312] Four cats of similar weight were selected for the experiment and divided into cats 1-4. Cats 1-3 were orally administered JWY-101 at a dose of 10 mg / kg, a single dose. Blood was collected 30 minutes before administration, and 5 minutes, 10 minutes, 30 minutes, 1 hour, 1.5 hours, 2 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, and 24 hours after administration. Cat No. 4 was used as a spare group for standby and blank matrix collection. The LC-MS / MS analysis method was used to detect the content of JWY-101 and GS441524 in plasma, and the quantitative limit of the method was 4 ng / mL. The plasma concentration data were statistically analyzed using the metabolic kinetic data analysis software WinNonlin 7.0, and the pharmacokinetic parameters were calculated using the non-compartmental model method (NCA).

[0313] The main pharmacokinetic parameters of JWY-101 in cats after administration are shown in Table 9:

[0314] Table 9 Main pharmacokinetic parameters of JWY-101 in cats after administration

[0315]

[0316] The mean concentration-time curve of JWY-101 in plasma after oral administration of 10 mg / kg JWY-101 to cats is shown in Fig. 9 .

[0317] 7. Experimental summary

[0318] In this example, JWY-101 was administered, and a small amount of prodrug JWY-101 was detected in cat plasma. This result shows that after oral administration of JWY-101 to cats, JWY-101 can effectively and quickly enter the systemic circulation.

[0319] Example 7: The compound JWY-101 synthesized in Example 2 was subjected to the following animal experiment

[0320] 1. Experimental subjects

[0321] A total of 8 sick cats diagnosed with feline infectious peritonitis were recruited from the pet hospital.

[0322] 2. Experimental plan

[0323] JWY-101 was prepared into a solution with normal saline and injected subcutaneously once a day.

[0324] JWY-101 was injected subcutaneously in the confirmed sick cats. The experimental cats were divided into a high-dose group and a medium-dose group. The dose of the high-dose group was 7 mg / kg, and the dose of the medium-dose group was 5 mg / kg.

[0325] Discharge criteria: mental state and appetite return to normal, pleural / peritoneal effusion decreases, other clinical symptoms are relieved or disappear, and the white-to-globulin ratio rises again and reaches around 0.4 or above 0.4.

[0326] 3. Detection indicators

[0327] Blood biochemical indexes

[0328] 4. Experimental results

[0329] Regularly review the treated cats during and after medication.

[0330] The blood white blood cell ratio of cats diagnosed with FIP after administration of JWY-101 is shown in Table 10:

[0331] Table 10 Record of blood leukocyte ratio of sick cats after administration of JWY-101

[0332]

[0333] The blood white blood cell ratio of cats diagnosed with feline infectious peritonitis after subcutaneous administration of 5mg / kg and 7mg / kg JWY-101 was shown in Fig.10 and Fig.11 .

[0334] Cats diagnosed with FIP were observed to have recovered their appetite and activity within 3 days of medication treatment; they all basically met the discharge criteria and were discharged after one week of medication treatment. Except for Fa Cai, whose data could not be tracked after being discharged from the hospital, all other sick cats recovered after treatment (their spirit and appetite returned to normal, pleural and abdominal effusion disappeared, intestinal lymph nodes were significantly reduced, and the white blood cell ratio returned to normal). As shown in Table 10, Fig.10 and Fig.11As shown in the figure, regardless of whether the sick cats were diagnosed with dry or wet infectious peritonitis, the white-globulin ratio of the sick cats recovered to varying degrees in a short period of time after JWY-101 administration; during the maintenance treatment until recovery, the white-globulin ratio of the sick cats gradually returned to a healthy value above 0.6. This result shows that subcutaneous administration of JWY-101 can quickly improve the spirit and appetite of sick cats, increase the white-globulin ratio, and effectively cure sick cats diagnosed with infectious peritonitis.

[0335] 5. Experimental conclusion

[0336] Our experimental results show that JWY-101 can quickly improve the spirit and appetite of cats diagnosed with infectious peritonitis (regardless of dry or wet) and increase the blood white blood cell ratio, effectively curing infectious peritonitis in cats, when JWY-101 is administered subcutaneously.

Claims

1. The compound shown in formula I: or a pharmaceutically acceptable salt; in: R1 and R2 are independently selected from H, or C1-C6 alkyl, 3-8 membered cycloalkyl or 6-20 membered aryl, and the alkyl, cycloalkyl, aryl may be further substituted by one or more independent substituents; m is an integer greater than 1; n is an integer greater than or equal to 0.

2. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein R1 and m are as defined in formula I, and R2=H and n=0; having the structure shown in the following chemical formula:

3. The compound according to claim 2 or a pharmaceutically acceptable salt thereof, wherein For Formula I, R1=CH3, m=2, R2=H and n=0; having the structure shown in the following chemical formula: Alternatively, for Formula I: R1=CH3, m=4, R2=H and n=0; having the structure shown in the following chemical formula:

4. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein For Formula I, R1=R2 and m=n; having the structure shown in the following chemical formula:

5. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein For formula I: R1=R2=CH3, m=n=2; its structure is shown below:

6. A pharmaceutical preparation comprising a pharmaceutically effective amount of the compound according to any one of claims 1 to 6 or a pharmaceutically acceptable salt thereof.

7. The pharmaceutical preparation according to claim 7, wherein The pharmaceutical preparation is a granule, capsule, tablet, pill, injection, suspension, solution, inhalant, powder aerosol or spray.

8. Use of a compound according to any one of claims 1 to 6 or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating or preventing viral infection in humans or animals.

9. The use according to claim 8, wherein the viral infection is a coronavirus infection.

10. The use according to claim 8, wherein the viral infection is feline FIPV virus infection.

11. A method for preparing the compound according to claim 1, wherein: include: (I) Prepare the intermediate int-1 with the following structure: (ii) synthesizing PEGylated phosphoric acid or its corresponding salt having the following structure: (III) The intermediate int-1 reacts with pegylated phosphoric acid or its corresponding salt to obtain the following compound: (IV) Removal of protecting groups: